Phase 1 Ovarian Cancer Trial, Recruiting (NCT05568680)

Phase 1 Ovarian Cancer Trial, Recruiting NCT05568680 Sponsor: Verismo Therapeutics Condition: Ovarian Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT05568680 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Ovarian Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed (confirmed by lab/pathology results) with one of these cancers that has come back or gotten worse: advanced ovarian cancer, primary peritoneal cancer, fallopian tube cancer, bile duct cancer (cholangiocarcinoma), or mesothelioma (affecting the lining of the lungs or abdomen)
You have already received at least one round of treatment (such as chemotherapy) for your advanced cancer
You are 18 years of age or older
You are generally able to carry out daily activities and care for yourself with little or no limitation (confirm with trial site for exact definition)
You have at least one area of cancer that can be measured on a scan
Your blood clotting is working within an acceptable range (confirm with trial site)
Your organs (such as liver and kidneys) and bone marrow are functioning well enough (confirm with trial site)

Who may not be able to join:

You currently have another active cancer, unless it was fully treated and has shown no signs of returning for at least 5 years
You have a history of certain blood or immune system cancers (T or B cell malignancies), or you have previously received a gene-based T cell treatment
You have a specific type of mesothelioma called sarcomatoid or biphasic mesothelioma
You have certain lung-related conditions (confirm with trial site for full details)
You have an immune system disorder, whether inherited, genetic, or acquired
You currently have active Hepatitis B, Hepatitis C, or HIV
You have an active autoimmune disease (a condition where your immune system attacks your own body)

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05568680

Sponsor: Verismo Therapeutics

Phase: Phase 1

Status: Recruiting

Condition: Ovarian Cancer

More information: https://clinicaltrials.gov/study/NCT05568680

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed (confirmed by lab/pathology results) with one of these cancers that has come back or gotten worse: advanced ovarian cancer, primary peritoneal cancer, fallopian tube cancer, bile duct cancer (cholangiocarcinoma), or mesothelioma (affecting the lining of the lungs or abdomen)
You have already received at least one round of treatment (such as chemotherapy) for your advanced cancer
You are 18 years of age or older
You are generally able to carry out daily activities and care for yourself with little or no limitation (confirm with trial site for exact definition)
You have at least one area of cancer that can be measured on a scan
Your blood clotting is working within an acceptable range (confirm with trial site)
Your organs (such as liver and kidneys) and bone marrow are functioning well enough (confirm with trial site)

Who may not be able to join:

You currently have another active cancer, unless it was fully treated and has shown no signs of returning for at least 5 years
You have a history of certain blood or immune system cancers (T or B cell malignancies), or you have previously received a gene-based T cell treatment
You have a specific type of mesothelioma called sarcomatoid or biphasic mesothelioma
You have certain lung-related conditions (confirm with trial site for full details)
You have an immune system disorder, whether inherited, genetic, or acquired
You currently have active Hepatitis B, Hepatitis C, or HIV
You have an active autoimmune disease (a condition where your immune system attacks your own body)

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 1

Sponsor

Verismo Therapeutics

Registry

ClinicalTrials.gov

Start date

30 March 2023

Est. completion

1 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Safety and Feasibility of SynKIR-110

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov